TACI-Fc fusion proteins, methods of making and uses thereof
View Patent ↗The subject invention relates generally to novel biologically active TACI-Fc fusion proteins that bind to BLyS and/or APRIL and uses thereof. The invention also relates to methods for recombinant production of homogeneous TACI-Fc fusion proteins on a large scale.
1. A TACI-Fc fusion protein that comprises a TACI polypeptide that consists of amino acids 13 to 119 of SEQ ID NO:1, or a fragment thereof, that starts at any of amino acids 13 to 29 of SEQ ID NO:1, extends through, and terminates at, any of amino acids 105 to 119 of SEQ ID NO:1 and which binds to BLyS or APRIL or both, or a variant of said polypeptide or fragment thereof that has at least 90% sequence identity with said polypeptide or fragment and which binds to BLyS or APRIL or both; and wherein said fusion protein further comprises an Fc domain.
2. The TACI-Fc fusion protein, according to claim 1 , wherein said variant polypeptide has at 95% sequence identity to amino acids 13 to 119 of SEQ ID NO:1 or said fragment thereof.
3. The TACI-Fc fusion protein, according to claim 1 , wherein the amino acid sequence of the TACI polypeptide terminates at amino acid 108 of SEQ ID NO:1.
4. The TACI-Fc fusion protein, according to claim 1 , wherein the amino acid of the TACI polypeptide terminates at amino acid 118 of SEQ ID NO:1.
5. The TACI-Fc fusion protein, according to claim 1 , wherein the Fc domain is selected from the group consisting of IgG, IgM, IgD, IgE, and IgA.
6. The TACI-Fc fusion protein, according to claim 5 , wherein the Fc domain is IgG1.
7. The TACI-Fc fusion protein, according to claim 1 , wherein the Fc domain comprises a hinge region, a CH2 region and a CH3 region.
8. The TACI-Fc fusion protein, according to claim 1 , further comprising a linker sequence that links the TACI polypeptide to the Fc domain.
9. The TACI-Fc fusion protein, according to claim 8 , wherein the linker sequence is SEQ ID NO: 18.
10. The TACI-Fc fusion protein, according to claim 1 , wherein the amino acid sequence of said TACI-Fc fusion protein is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.
11. The TACI-Fc fusion protein, according to claim 1 , wherein the variant of said polypeptide or fragment thereof has at least 97% sequence identity with said polypeptide or fragment, and the variant binds to BLyS or APRIL or both.
12. The TACI-Fc fusion protein, according to claim 1 , wherein the TACI polypeptide consists of amino acids 13 to 119 of SEQ ID NO:1; or a fragment thereof that starts at any of amino acids 13 to 29 of SEQ ID NO:1, extends through, and terminates at, any of amino acids 105 to 119 of SEQ ID NO:1.
13. A TACI-Fc fusion protein that comprises a TACI polypeptide consisting of SEQ ID NO:1 or a fragment thereof that binds to BlyS or APRIL or both wherein said fragment comprises amino acids 30 to 104 of SEQ ID NO:1, and which has had the PC cleavage sites at amino acids 12 and 120 removed.
14. A pharmaceutical composition comprising a TACI-Fc fusion protein of claim 1 and a pharmaceutically acceptable carrier.
15. A method for recombinant production of homogeneous TACI-Fc fusion proteins, wherein said method comprises:
i) constructing a TACI DNA fragment encoding a TACI polypeptide comprising at least a part of the amino terminal region consisting of amino acids 13-29 of SEQ ID NO:1, a cystein-rich region, and at least a part of the stalk region, wherein the TACI DNA encodes a TACI polypeptide that does not contain proprotein cleavage sites;
ii) joining the TACI DNA fragment with a Fc DNA to obtain a TACI-Fc fusion DNA;
iii) inserting the TACI-Fc fusion DNA into a plasmid;
iv) transfecting host cells with the TACI-Fc fusion plasmid DNA,
v) expressing the TACI-Fc fusion protein, and
vi) recovering the TACI-Fc fusion protein.